skip to content

Cambridge Immunology Network



The tumour microenvironment can be challenging to target for the immune system, as it can develop several immunosuppressive mechanisms that inhibit the correct function of the T cells. However, the T cells can be modified to enhance this response and eliminate the tumour cells. I found this fascinating, and I am working to identify new targets to enhance T cell survival and/or function within the tumour microenvironment.


During my doctoral studies, I worked on new strategies for cancer immunotherapy. I worked on inhibition of regulatory T cells using viral vector and aptamers to carrying different siRNA and gRNAs. I used also combinations of antitumoral vaccines that expressed immunomodulators like 4-1BBL, OX40L, and GM-CSF to enhance the immune response against cancer.


Key publications: 

Manrique-Rincón AJ, Beraldo CM, Toscaro JM, Bajgelman MC. exploring synergy in combinations of Tumor-Derived Vaccines That harbor 4-1BBl, OX40l, and gM-csF. Frontiers in immunology. 2017 Sep 19;8:1150.

Not available for consultancy